Business Context and Reporting Period
This Form 8-K filing by Rexahn Pharmaceuticals, Inc. (trading symbol: REXN) reports on events occurring on November 2, 2020. The filing details the results of a Special Meeting of Stockholders held to approve a merger with Ocuphire Pharma, Inc., a corporate name change, a reverse stock split, and the adoption of a new equity incentive plan.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and voting results.
Material Changes and Voting Results
Stockholders approved six key proposals at the Special Meeting. As of the record date (September 25, 2020), 4,483,198 shares were outstanding, with 74.46% represented at the meeting. The approved proposals include:
- Merger and Change of Control: Approval of the issuance of common stock to Ocuphire stockholders and the resulting change of control.
- Reverse Stock Split: Approval to amend the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-3 and 1-for-5.
- Corporate Name Change: Approval to change the company name from "Rexahn Pharmaceuticals, Inc." to "Ocuphire Pharma, Inc."
- Equity Incentive Plan: Approval of the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan, reserving 4,000,000 new shares plus up to 4,252,985 additional shares from prior plans.
- Pre-Merger Financing: Approval of the issuance of shares in connection with pre-merger financing warrants and additional shares.
- Adjournment: Approval to adjourn the meeting if necessary to solicit additional proxies (not required as sufficient votes were obtained).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard context of the merger transaction. The Ocuphire 2020 Plan will become effective upon the closing of the merger transactions contemplated by the Merger Agreement dated June 17, 2020.
Investor Verification Checklist
- Verify the specific reverse stock split ratio (1-for-3 to 1-for-5) to be determined by the Board of Directors.
- Confirm the closing date of the merger with Ocuphire Pharma, Inc. to determine when the name change and new equity plan become effective.
- Review the definitive proxy statement filed on October 2, 2020, for detailed terms of the Ocuphire 2020 Equity Incentive Plan.
- Monitor the issuance of shares related to the pre-merger financing warrants.